KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.

ABSTRACT:

Introduction

Oncogenic mutation within the KRAS gene represents a negative predictor for treatment response to anti-epidermal growth factor receptor (EGFR) in patients with colorectal cancer. Recently, we have shown no relevant heterogeneity for KRAS mutation status within and between pre- and posttherapeutic samples from the primary tumor in patients with locally advanced rectal cancer. The aim of this study was to evaluate the intertumoral heterogeneity of KRAS mutation status between the primary tumor and the corresponding metastasis or local recurrence in the similar cohort and to evaluate the ideal representative tissue for KRAS mutation testing.

Materials and methods

KRAS mutation status was analyzed from 47 patients with locally advanced rectal cancer, which were enro

SUBMITTER: Jo P 

PROVIDER: S-EPMC7529221 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature